BVS - Bioventus sees Q1 sales in line with consensus

Bioventus (NASDAQ:BVS) has reported Q1 prelim net sales of $116.5M to $118.5M vs. $117.76M consensus. That would indicate a 42% to 45% growth over the prior-year period. Prelim net loss and adj. EBITDA are estimated to be in the range of -$19.4M and -$19M and $6.8M to $7.3M, respectively. The adj. EBITDA figure does not reflect the estimated impact from the firm's acquisition of CartiHeal. CEO Ken Reali stated, "We continued to deliver above-market revenue growth in Pain Treatments and saw monthly sequential improvements in Surgical Solutions revenue growth as elective procedures began to steadily recover in the second half of the quarter."

For further details see:

Bioventus sees Q1 sales in line with consensus